Stammdaten
Belite Bio, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Entwicklungsstadium mit Sitz in San Diego, Kalifornien. Das Unternehmen konzentriert sich auf die Entwicklung von Therapien für degenerative Netzhauterkrankungen wie geografische Atrophie (GA) und Stargardt-Krankheit Typ 1 (STGD1). Der Hauptproduktkandidat des Unternehmens ist Tinlarebant (LBS-008), ein oral verabreichter Wirkstoff, der zur Behandlung von GA und STGD1 entwickelt wurde. Tinlarebant zielt darauf ab, die Bindung von Vitamin A an das Serum-Retinol-bindende Protein 4 (RBP4) zu stören, wodurch die Zufuhr von Retinol zum Auge reduziert und die Ansammlung toxischer Vitamin-A-Nebenprodukte verringert wird. Das Unternehmen hat mehrere klinische Studien durchgeführt, darunter eine Phase-3-Studie namens DRAGON bei STGD1-Patienten im Alter von 12 bis 20 Jahren sowie eine Phase-3-Studie namens PHOENIX bei GA-Patienten. Belite Bio verfügt über ein weltweites exklusives Lizenzrecht am RBP4-IP-Portfolio der Columbia University, das über 400 strukturell unterschiedliche RBP4-Antagonisten umfasst. Neben Tinlarebant entwickelt das Unternehmen auch LBS-009, eine oral verabreichte Verbindung zur Behandlung metabolischer Erkrankungen wie nicht-alkoholische Fettlebererkrankung (NAFLD), nicht-alkoholische Steatohepatitis (NASH), Typ-2-Diabetes und Gicht. Das Unternehmen hat mehrere Tochtergesellschaften in verschiedenen Ländern, darunter Australien, China, Taiwan, Japan und der Schweiz, die klinische Studien und Forschungsaktivitäten unterstützen. KI
Unternehmen & Branche
| Name | BELITE BIO, INC |
|---|---|
| Ticker | BLTE |
| CIK | 0001889109 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 07782B104 |
|---|---|
| ISIN | US07782B1044 |
| Typ | ADR |
| Marktkapitalisierung | 6,12 Mrd. USD |
| Beta | -1,15 |
| Dividendenrendite | 0,00 % |
Sitz & Kontakt
| Sitz (Inkorporation) | Cayman Islands |
|---|---|
| Geschäftsadresse | 12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO, CA |
| Telefon | 858-246-6240 |
| EIN (IRS) | 00-0000000 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
BLTE
BELITE BIO, INC
ⓘ
Eingeschränkte Aussagekraft — erst 59 % der Signal-Gewichte sind mit Daten unterlegt.
🟢
Günstiges Einstiegsfenster — fundamental starke Aktie, deren Timing gerade positiv dreht. Laut Modell aktuell der attraktivste Einstiegszeitpunkt.
Effektiv
Stark
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
38,3
28 neu, 25 erhöht, 206,0M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 146.55 | +4.3 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 146.47 | +4.4 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 149.41 | EMA50: 149.79 | |
| MACD-Histogramm | Bullisch | 10 % | 0.050 | Bullisch | |
| RSI(14) | Neutral | 10 % | 54.6 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 66.2 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 11.3 | +DI: 21.0 / −DI: 16.3 | |
| Z-Score(60) | Neutral | 5 % | 0.62 | In Range | |
| 52W-Position | Neutral | 5 % | 71.3 % | Hoch 190.30 / Tief 59.68 | |
| Bollinger(20,2σ) | Neutral | 5 % | 68.8 % | Upper 157.37 / Mid 150.12 / Lower 142.87 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.1122 | R²=0.08 / annualisiert -19.0 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -1.199 | 146,24 | -175.347,64 | -257,1% | |
| 2026-06-18 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -96 | 147,11 | -14.122,56 | -20,7% | |
| 2026-06-18 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -96 | 143,90 | -13.814,40 | -20,3% | |
| 2026-06-18 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -3.748 | 144,66 | -542.192,05 | -795,0% | |
| 2026-06-18 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -4.861 | 145,43 | -706.958,56 | -1036,6% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -784 | 138,18 | -108.330,53 | -158,8% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -540 | 140,58 | -75.914,71 | -111,3% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -100 | 141,83 | -14.183,00 | -20,8% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -450 | 142,20 | -63.988,11 | -93,8% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -3.140 | 139,57 | -438.260,48 | -642,6% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -2.054 | 137,61 | -282.641,29 | -414,4% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -1.897 | 143,55 | -272.314,35 | -399,3% | |
| 2026-06-16 | Scholl Hendrik Peter | Officer, Chief Medical Officer | Open Market Sale | -1.035 | 145,02 | -150.096,94 | -220,1% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -9 | 155,25 | -1.397,28 | -2,0% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -428 | 153,56 | -65.725,18 | -96,4% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -226 | 152,45 | -34.453,09 | -50,5% | |
| 2026-05-07 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 154,61 | -463,83 | -0,7% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -100 | 155,97 | -15.597,00 | -22,9% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -424 | 152,67 | -64.732,80 | -94,9% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -240 | 154,41 | -37.058,81 | -54,3% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -128 | 153,42 | -19.637,54 | -28,8% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -100 | 156,00 | -15.600,00 | -22,9% | |
| 2026-05-06 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 151,57 | -1.212,56 | -1,8% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -120 | 153,92 | -18.470,60 | -27,1% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -363 | 154,44 | -56.062,92 | -82,2% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -173 | 155,48 | -26.897,54 | -39,4% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -155 | 157,29 | -24.379,90 | -35,7% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -121 | 156,53 | -18.940,03 | -27,8% | |
| 2026-05-05 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -68 | 158,11 | -10.751,48 | -15,8% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -325 | 155,21 | -50.441,95 | -74,0% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -236 | 154,24 | -36.400,05 | -53,4% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -235 | 156,57 | -36.793,41 | -54,0% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -172 | 157,49 | -27.088,35 | -39,7% | |
| 2026-05-04 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -32 | 153,50 | -4.911,84 | -7,2% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -23 | 160,00 | -3.680,00 | -5,4% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -346 | 155,48 | -53.794,70 | -78,9% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -288 | 154,38 | -44.461,35 | -65,2% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -106 | 157,45 | -16.689,89 | -24,5% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -82 | 156,24 | -12.811,80 | -18,8% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -65 | 158,35 | -10.292,62 | -15,1% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -52 | 153,89 | -8.002,50 | -11,7% | |
| 2026-05-01 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -38 | 159,08 | -6.044,98 | -8,9% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -101 | 158,15 | -15.972,68 | -23,4% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -517 | 156,59 | -80.955,27 | -118,7% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -340 | 157,37 | -53.506,38 | -78,5% | |
| 2026-04-30 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -42 | 155,68 | -6.538,42 | -9,6% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -102 | 157,39 | -16.053,36 | -23,5% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -339 | 156,43 | -53.029,91 | -77,8% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -278 | 154,58 | -42.972,68 | -63,0% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -259 | 155,52 | -40.280,41 | -59,1% | |
| 2026-04-29 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -22 | 158,19 | -3.480,27 | -5,1% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -53 | 156,61 | -8.300,42 | -12,2% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -380 | 159,42 | -60.579,30 | -88,8% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -222 | 157,49 | -34.962,11 | -51,3% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -120 | 160,27 | -19.232,90 | -28,2% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -89 | 161,72 | -14.393,14 | -21,1% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 155,36 | -1.242,87 | -1,8% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -62 | 158,71 | -9.840,06 | -14,4% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -54 | 162,14 | -8.755,69 | -12,8% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -12 | 154,65 | -1.855,76 | -2,7% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -231 | 162,38 | -37.509,20 | -55,0% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -36 | 164,07 | -5.906,58 | -8,7% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -44 | 160,83 | -7.076,72 | -10,4% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -280 | 161,62 | -45.253,91 | -66,4% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -409 | 163,56 | -66.894,94 | -98,1% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 162,53 | -487,59 | -0,7% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -375 | 159,46 | -59.797,54 | -87,7% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -330 | 160,40 | -52.931,31 | -77,6% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -190 | 158,65 | -30.142,89 | -44,2% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -74 | 157,86 | -11.681,98 | -17,1% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -28 | 161,22 | -4.514,20 | -6,6% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -54 | 168,43 | -9.095,43 | -13,3% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -373 | 167,37 | -62.430,61 | -91,5% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -267 | 164,47 | -43.914,40 | -64,4% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -158 | 165,38 | -26.129,39 | -38,3% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -127 | 166,56 | -21.153,23 | -31,0% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -21 | 169,56 | -3.560,69 | -5,2% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -21 | 173,04 | -3.633,86 | -5,3% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -257 | 171,62 | -44.105,06 | -64,7% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -249 | 172,49 | -42.950,03 | -63,0% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -141 | 167,42 | -23.606,30 | -34,6% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -105 | 169,52 | -17.799,98 | -26,1% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -101 | 168,64 | -17.032,19 | -25,0% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -75 | 170,58 | -12.793,75 | -18,8% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -31 | 165,70 | -5.136,73 | -7,5% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -20 | 166,32 | -3.326,40 | -4,9% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -78 | 164,60 | -12.838,85 | -18,8% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -332 | 165,49 | -54.943,84 | -80,6% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -312 | 166,49 | -51.943,57 | -76,2% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -214 | 167,34 | -35.810,46 | -52,5% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -64 | 163,49 | -10.463,67 | -15,3% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -40 | 165,29 | -6.611,74 | -9,7% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -524 | 163,52 | -85.684,11 | -125,6% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -284 | 162,76 | -46.222,48 | -67,8% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -124 | 164,40 | -20.385,71 | -29,9% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -16 | 167,17 | -2.674,64 | -3,9% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -9 | 168,35 | -1.515,15 | -2,2% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 166,91 | -500,72 | -0,7% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -274 | 161,41 | -44.226,12 | -64,8% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -226 | 160,55 | -36.283,71 | -53,2% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -216 | 162,48 | -35.096,39 | -51,5% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -200 | 163,33 | -32.665,00 | -47,9% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -52 | 159,38 | -8.287,96 | -12,2% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -32 | 158,46 | -5.070,60 | -7,4% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -12 | 164,12 | -1.969,48 | -2,9% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -36 | 163,21 | -5.875,60 | -8,6% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -240 | 161,61 | -38.786,33 | -56,9% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -219 | 159,81 | -34.999,09 | -51,3% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -216 | 158,28 | -34.188,13 | -50,1% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -201 | 160,35 | -32.229,85 | -47,3% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -76 | 162,26 | -12.332,05 | -18,1% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 170,77 | -1.366,12 | -2,0% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -537 | 168,64 | -90.562,04 | -132,8% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -383 | 167,58 | -64.182,83 | -94,1% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -68 | 169,15 | -11.502,36 | -16,9% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -4 | 171,19 | -684,76 | -1,0% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -2.500 | 180,36 | -450.894,50 | -661,2% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -2.000 | 181,40 | -362.790,00 | -532,0% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -2.000 | 180,35 | -360.695,00 | -528,9% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -1.909 | 182,58 | -348.541,78 | -511,1% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -291 | 183,08 | -53.276,66 | -78,1% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -3.500 | 181,33 | -634.656,40 | -930,6% | |
| 2026-04-09 | Chen Wan-Shan | Director | Open Market Sale | -1.100 | 180,43 | -198.473,11 | -291,0% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -3.000 | 182,40 | -547.188,00 | -802,3% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 183,00 | -36.600,00 | -53,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.057.412 | 0 | 3.057.412 | 456.104.722 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 1.114.784 | 0 | 1.114.784 | 177.741.161 | Neu | +100,0% | |
| UBS Group AG | 768.359 | 0 | 768.359 | 122.507.159 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 715.332 | 0 | 715.332 | 114.052.534 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 570.088 | 0 | 570.088 | 90.894.831 | Neu | +100,0% | |
| Holocene Advisors, LP | 494.495 | 0 | 494.495 | 78.842.283 | Neu | +100,0% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 357.650 | 0 | 357.650 | 57.023.716 | Neu | +100,0% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 304.013 | 0 | 304.013 | 48.471.833 | Neu | +100,0% | |
| MORGAN STANLEY | 201.409 | 0 | 201.409 | 32.112.649 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 151.979 | 0 | 151.979 | 24.231.532 | Neu | +100,0% | |
| Patient Square Capital LP | 116.684 | 0 | 116.684 | 18.604.097 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 105.509 | 0 | 105.509 | 16.822.355 | Neu | +100,0% | |
| MPM BioImpact LLC | 88.045 | 0 | 88.045 | 14.037.895 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 65.000 | 0 | 65.000 | 10.363.600 | Neu | +100,0% | |
| FRED ALGER MANAGEMENT, LLC | 62.574 | 0 | 62.574 | 9.976.799 | Neu | +100,0% | |
| PFM Health Sciences, LP | 59.432 | 0 | 59.432 | 9.475.838 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 52.000 | 0 | 52.000 | 8.290.880 | Neu | +100,0% | |
| Longaeva Partners L.P. | 33.492 | 0 | 33.492 | 5.339.964 | Neu | +100,0% | |
| TD ASSET MANAGEMENT INC | 33.410 | 0 | 33.410 | 5.326.890 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 32.525 | 0 | 32.525 | 5.185.786 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 26.880 | 0 | 26.880 | 4.285.747 | Neu | +100,0% | |
| Quadrature Capital Ltd | 23.708 | 0 | 23.708 | 3.780.004 | Neu | +100,0% | |
| Aquatic Capital Management LLC | 20.294 | 0 | 20.294 | 3.235.675 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 19.600 | 0 | 19.600 | 3.125.024 | Neu | +100,0% | |
| Squarepoint Ops LLC | 16.981 | 0 | 16.981 | 2.707.451 | Neu | +100,0% | |
| STATE STREET CORP | 16.048 | 0 | 16.048 | 2.558.693 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 15.981 | 0 | 15.981 | 2.548.011 | Neu | +100,0% | |
| Trexquant Investment LP | 15.072 | 0 | 15.072 | 2.403.080 | Neu | +100,0% | |
| XTX Topco Ltd | 15.058 | 0 | 15.058 | 2.400.848 | Neu | +100,0% | |
| BALANCE CAPITAL PARTNERS L.P. | 14.500 | 0 | 14.500 | 2.311.880 | Neu | +100,0% | |
| Verdad Advisers, LP | 13.813 | 0 | 13.813 | 2.202.345 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 12.222 | 0 | 12.222 | 1.948.676 | Neu | +100,0% | |
| Blackstone Inc. | 10.692 | 0 | 10.692 | 1.704.732 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 10.427 | 0 | 10.427 | 1.662.480 | Neu | +100,0% | |
| HighVista Strategies LLC | 8.033 | 0 | 8.033 | 1.280.781 | Neu | +100,0% | |
| Voleon Capital Management LP | 7.883 | 0 | 7.883 | 1.256.866 | Neu | +100,0% | |
| BARCLAYS PLC | 6.822 | 0 | 6.822 | 1.087.700 | Neu | +100,0% | |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 6.004 | 0 | 6.004 | 957.278 | Neu | +100,0% | |
| Amundi | 4.210 | 0 | 4.210 | 671.242 | Neu | +100,0% | |
| SmartHarvest Portfolios, LLC | 4.187 | 0 | 4.187 | 667.575 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 3.778 | 0 | 3.778 | 602.365 | Neu | +100,0% | |
| High Net Worth Advisory Group LLC | 3.500 | 0 | 3.500 | 558.040 | Neu | +100,0% | |
| Convergence Financial, LLC | 2.968 | 0 | 2.968 | 473.222 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 2.767 | 0 | 2.767 | 441.170 | Neu | +100,0% | |
| Engineers Gate Manager LP | 2.489 | 0 | 2.489 | 396.846 | Neu | +100,0% | |
| AXQ CAPITAL, LP | 2.372 | 0 | 2.372 | 378.192 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 2.257 | 0 | 2.257 | 360.000 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 2.008 | 0 | 2.008 | 320.156 | Neu | +100,0% | |
| Virtus Investment Advisers, LLC | 1.929 | 0 | 1.929 | 307.560 | Neu | +100,0% | |
| DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. | 1.900 | 0 | 1.900 | 302.936 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| GAMMA Investing LLC | 1.686 | 1.707 | -1,2% | 259.619 | 92,59 | 100 % | 11 Q |
| E Fund Management (Hong Kong) Co., Ltd. | 113 | 83 | +36,1% | 17.400 | 6,21 | 100 % | 2 Q |
| WEST PACES ADVISORS INC. | 18 | 0 | +100,0% | 2.772 | 0,99 | 100 % | 1 Q |
| Farther Finance Advisors, LLC | 4 | 15 | -73,3% | 616 | 0,22 | 0 % | 3 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 4 | 0,0 | 0 |
| 31.03.2026 | ✓ | 74 | 9,3 | 1.381 |
| 31.12.2025 | ✓ | 68 | 7,3 | 1.168 |
| 30.09.2025 | ✓ | 34 | 2,3 | 171 |
| 30.06.2025 | ✓ | 18 | 0,1 | 5 |
| 31.03.2025 | ✓ | 18 | 0,3 | 10 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Paradigm Biocapital Advisors LP | 1.114.784 | 177.741.161 |
| Patient Square Capital LP | 116.684 | 18.604.097 |
| RENAISSANCE TECHNOLOGIES LLC | 52.000 | 8.290.880 |
| Longaeva Partners L.P. | 33.492 | 5.339.964 |
| TD ASSET MANAGEMENT INC | 33.410 | 5.326.890 |
| Aquatic Capital Management LLC | 20.294 | 3.235.675 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 19.600 | 3.125.024 |
| Squarepoint Ops LLC | 16.981 | 2.707.451 |
| Trexquant Investment LP | 15.072 | 2.403.080 |
| XTX Topco Ltd | 15.058 | 2.400.848 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| UBS Group AG | 768.359 | 639.607 | +496.8 % | 122.507.159 |
| Holocene Advisors, LP | 494.495 | 410.428 | +488.2 % | 78.842.283 |
| MORGAN STANLEY | 201.409 | 173.396 | +619.0 % | 32.112.649 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 304.013 | 70.200 | +30.0 % | 48.471.833 |
| GOLDMAN SACHS GROUP INC | 105.509 | 60.910 | +136.6 % | 16.822.355 |
| Affinity Asset Advisors, LLC | 65.000 | 45.000 | +225.0 % | 10.363.600 |
| PFM Health Sciences, LP | 59.432 | 39.609 | +199.8 % | 9.475.838 |
| BNP PARIBAS FINANCIAL MARKETS | 32.525 | 30.077 | +1228.6 % | 5.185.786 |
| Darwin Global Management, Ltd. | 3.057.412 | 29.708 | +1.0 % | 456.104.722 |
| MILLENNIUM MANAGEMENT LLC | 570.088 | 11.206 | +2.0 % | 90.894.831 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 151.979 | -262.260 | -63.3 % | 24.231.532 |
| EVENTIDE ASSET MANAGEMENT, LLC | 357.650 | -25.441 | -6.6 % | 57.023.716 |
| JANE STREET GROUP, LLC | 12.222 | -20.096 | -62.2 % | 1.948.676 |
| FRED ALGER MANAGEMENT, LLC | 62.574 | -16.820 | -21.2 % | 9.976.799 |
| ADAR1 Capital Management, LLC | 26.880 | -12.959 | -32.5 % | 4.285.747 |
| CITADEL ADVISORS LLC | 2.008 | -3.047 | -60.3 % | 320.156 |
| CITIGROUP INC | 1 | -2.136 | -100.0 % | 159 |
| Quadrature Capital Ltd | 23.708 | -1.124 | -4.5 % | 3.780.004 |
| SG Americas Securities, LLC | 2.144 | -611 | -22.2 % | 342 |
| Caitong International Asset Management Co., Ltd | 349 | -200 | -36.4 % | 55.645 |
Zusätzlich aktuell von 21 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 14.05.2026 | Yu-Hsin Lin | Passiv (13G/A) | 3,10 % | 1.253.935 | -4,00 pp | |
| 17.02.2026 | Darwin Global Management, Ltd. (+1) | Passiv (13G/A) | 8,10 % | 3.027.704 | +1,10 pp | |
| 17.02.2026 | Darwin Global Master Fund, Ltd. | Passiv (13G/A) | 7,80 % | 2.928.575 | +1,10 pp | |
| 10.12.2025 | Darwin Global Management, Ltd. (+1) | Passiv (13G) | 7,00 % | 2.617.094 | Neu | |
| 10.12.2025 | Darwin Global Master Fund, Ltd. | Passiv (13G) | 6,70 % | 2.527.589 | Neu | |
| 21.01.2025 | Yu-Hsin Lin | Passiv (13G) | 7,10 % | 2.287.070 | Neu | |
| 21.01.2025 | Lin Bioscience International Ltd. | Passiv (13G) | 53,70 % | 17.095.263 | Neu |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 15.06.2026 | 6-K | – | – | SEC » |
| 20.05.2026 | 6-K | – | – | SEC » |
| 21.04.2026 | 6-K | – | – | SEC » |
| 31.03.2026 | 20-F | – | – | SEC » |
| 31.03.2026 | 6-K | – | – | SEC » |
| 02.03.2026 | 6-K | – | – | SEC » |
| 27.01.2026 | 6-K | – | – | SEC » |
| 02.12.2025 | 6-K | – | – | SEC » |
| 01.12.2025 | 6-K | – | – | SEC » |
| 01.12.2025 | 6-K | – | – | SEC » |
| 01.12.2025 | 6-K | – | – | SEC » |
| 10.11.2025 | 6-K | – | – | SEC » |
| 08.09.2025 | 6-K | – | – | SEC » |
| 11.08.2025 | 6-K | – | – | SEC » |
| 07.08.2025 | 6-K | – | – | SEC » |
| 02.07.2025 | 6-K | – | – | SEC » |
| 21.05.2025 | 6-K | – | – | SEC » |
| 14.05.2025 | 6-K | – | – | SEC » |
| 15.04.2025 | 6-K | – | – | SEC » |
| 28.03.2025 | 6-K | – | – | SEC » |
| 18.03.2025 | 6-K | – | – | SEC » |
| 17.03.2025 | 20-F | – | – | SEC » |
| 17.03.2025 | 6-K | – | – | SEC » |
| 17.03.2025 | 6-K | – | – | SEC » |
| 27.02.2025 | 6-K | – | – | SEC » |
| 06.02.2025 | 6-K | – | – | SEC » |
| 12.03.2024 | 20-F | – | – | SEC » |
| 31.03.2023 | 20-F | – | – | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 02.12.2025 | Kapitalerhöhung | $350,0 Mio · $154,00/Aktie | SEC » |
| 01.12.2025 | Kapitalerhöhung | – | SEC » |
| 08.08.2025 | Kapitalerhöhung | $15,0 Mio · $65,00/Aktie | SEC » |
| 07.02.2025 | Kapitalerhöhung | $1,5 Mio · $58,07/Aktie | SEC » |
| 29.04.2024 | Kapitalerhöhung | – | SEC » |
| 16.06.2023 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 01.06.2023 | Kapitalerhöhung | $28,2 Mio · $15,00/Aktie | SEC » |
| 30.05.2023 | Kapitalerhöhung | – | SEC » |
| 29.04.2022 | Börsengang | $36,0 Mio · $6,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 1 | 154,65 | 155 |
| 2026-06-03 | 10.209 | 134,93 | 1.377.500 |
| 2026-06-02 | 444 | 147,00 | 65.268 |
| 2026-04-16 | 500 | 168,76 | 84.380 |
| 2026-04-08 | 5 | 169,79 | 849 |
| 2026-04-02 | 540 | 167,25 | 90.315 |
| 2026-03-26 | 879 | 155,04 | 136.280 |
| 2026-03-25 | 869 | 150,83 | 131.071 |
| 2026-03-19 | 371 | 161,34 | 59.857 |
| 2026-03-18 | 253 | 161,41 | 40.837 |
| 2026-03-16 | 261 | 164,11 | 42.833 |
| 2026-03-13 | 371 | 169,55 | 62.903 |
| 2026-03-10 | 1.360 | 179,12 | 243.603 |
| 2026-03-06 | 109 | 172,57 | 18.810 |
| 2026-03-05 | 4.392 | 177,79 | 780.854 |
| 2026-03-04 | 18.703 | 167,88 | 3.139.860 |
| 2026-03-03 | 4.099 | 177,58 | 727.900 |
| 2026-03-02 | 238 | 190,30 | 45.291 |
| 2026-02-27 | 373 | 188,55 | 70.329 |
| 2026-02-17 | 1 | 175,26 | 175 |
| 2026-02-09 | 2 | 187,86 | 376 |
| 2026-01-26 | 6.935 | 164,58 | 1.141.362 |